ANI Pharmaceuticals says it has drawn level with rival Amneal in the field of US competitive generic therapies after receiving US Food and Drug Administration approval for and launching two new CGTs.
Announcing the FDA approval for and commercialization of the pair new abbreviated new drug applications with attached 180-day CGT exclusivity, ANI said the two products were methsuximide 300mg capsules – a generic version of Celontin –
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?